These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 25512383)

  • 1. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.
    Wang R; You J
    J Biol Chem; 2015 Jan; 290(5):2744-58. PubMed ID: 25512383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.
    Alekseyenko AA; Walsh EM; Zee BM; Pakozdi T; Hsi P; Lemieux ME; Dal Cin P; Ince TA; Kharchenko PV; Kuroda MI; French CA
    Proc Natl Acad Sci U S A; 2017 May; 114(21):E4184-E4192. PubMed ID: 28484033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.
    Yan J; Diaz J; Jiao J; Wang R; You J
    J Biol Chem; 2011 Aug; 286(31):27663-75. PubMed ID: 21652721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
    Wang R; Liu W; Helfer CM; Bradner JE; Hornick JL; Janicki SM; French CA; You J
    Cancer Res; 2014 Jun; 74(12):3332-43. PubMed ID: 24736545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains.
    Reynoird N; Schwartz BE; Delvecchio M; Sadoul K; Meyers D; Mukherjee C; Caron C; Kimura H; Rousseaux S; Cole PA; Panne D; French CA; Khochbin S
    EMBO J; 2010 Sep; 29(17):2943-52. PubMed ID: 20676058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
    Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
    Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural mechanism of BRD4-NUT and p300 bipartite interaction in propagating aberrant gene transcription in chromatin in NUT carcinoma.
    Yu D; Liang Y; Kim C; Jaganathan A; Ji D; Han X; Yang X; Jia Y; Gu R; Wang C; Zhang Q; Cheung KL; Zhou MM; Zeng L
    Nat Commun; 2023 Jan; 14(1):378. PubMed ID: 36690674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supercharging BRD4 with NUT in carcinoma.
    Eagen KP; French CA
    Oncogene; 2021 Feb; 40(8):1396-1408. PubMed ID: 33452461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
    Shiota H; Alekseyenko AA; Wang ZA; Filic I; Knox TM; Luong NM; Huang Y; Scott DA; Jones KL; Gokhale PC; Lemieux ME; Cole PA; Kuroda MI; French CA
    Mol Cancer Res; 2021 Nov; 19(11):1818-1830. PubMed ID: 34285087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.
    Thompson-Wicking K; Francis RW; Stirnweiss A; Ferrari E; Welch MD; Baker E; Murch AR; Gout AM; Carter KW; Charles AK; Phillips MB; Kees UR; Beesley AH
    Oncogene; 2013 Sep; 32(39):4664-74. PubMed ID: 23128391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.
    French CA; Ramirez CL; Kolmakova J; Hickman TT; Cameron MJ; Thyne ME; Kutok JL; Toretsky JA; Tadavarthy AK; Kees UR; Fletcher JA; Aster JC
    Oncogene; 2008 Apr; 27(15):2237-42. PubMed ID: 17934517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains.
    Alekseyenko AA; Walsh EM; Wang X; Grayson AR; Hsi PT; Kharchenko PV; Kuroda MI; French CA
    Genes Dev; 2015 Jul; 29(14):1507-23. PubMed ID: 26220994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular features driving condensate formation and gene expression by the BRD4-NUT fusion oncoprotein are overlapping but distinct.
    Kosno M; Currie SL; Kumar A; Xing C; Rosen MK
    Sci Rep; 2023 Jul; 13(1):11907. PubMed ID: 37488172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.
    French CA; Rahman S; Walsh EM; Kühnle S; Grayson AR; Lemieux ME; Grunfeld N; Rubin BP; Antonescu CR; Zhang S; Venkatramani R; Dal Cin P; Howley PM
    Cancer Discov; 2014 Aug; 4(8):928-41. PubMed ID: 24875858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
    Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
    Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function.
    Sakamaki JI; Wilkinson S; Hahn M; Tasdemir N; O'Prey J; Clark W; Hedley A; Nixon C; Long JS; New M; Van Acker T; Tooze SA; Lowe SW; Dikic I; Ryan KM
    Mol Cell; 2017 May; 66(4):517-532.e9. PubMed ID: 28525743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
    Gen Y; Muramatsu T; Inoue J; Inazawa J
    Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-Molecule Targeting of BET Proteins in Cancer.
    French CA
    Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.
    Grayson AR; Walsh EM; Cameron MJ; Godec J; Ashworth T; Ambrose JM; Aserlind AB; Wang H; Evan G; Kluk MJ; Bradner JE; Aster JC; French CA
    Oncogene; 2014 Mar; 33(13):1736-1742. PubMed ID: 23604113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.